AGRX Stock Overview
Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Agile Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.40 |
52 Week High | US$6.97 |
52 Week Low | US$0.20 |
Beta | 1.4 |
1 Month Change | 19.76% |
3 Month Change | -74.68% |
1 Year Change | -93.94% |
3 Year Change | -99.99% |
5 Year Change | -99.99% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Agile appoints chief commercial officer from within ranks amid leadership revamp
Oct 10Agile gains as H.C. Wainwright sees 630% upside potential
Jul 11Agile Therapeutics prices $24M upsized stock offering
Jul 01Agile Therapeutics: Twirla's Lackluster Launch Forces Me To Change My Strategy
Apr 04Agile Therapeutics: Bullish On Capitulation And Max Pain
Oct 19Agile Therapeutics: Another Quarter Of Progress And Another Opportunity To Buy
Jul 30Agile Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 06How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Did Insiders Buy, In The Last Year?
Feb 25Agile Therapeutics issues cash projection at JP Morgan healthcare conference
Jan 14Assessing Agile Therapeutics
Jan 10How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Do Institutions Own?
Jan 04Agile Therapeutics announces peer-reviewed publication of late-stage study for Twirla contraception patch
Nov 30Agile Therapeutics EPS in-line
Nov 12Shareholder Returns
AGRX | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 8.1% | -0.6% | 1.0% |
1Y | -93.9% | 10.6% | 21.9% |
Return vs Industry: AGRX underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: AGRX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
AGRX volatility | |
---|---|
AGRX Average Weekly Movement | 21.8% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AGRX's share price has been volatile over the past 3 months.
Volatility Over Time: AGRX's weekly volatility has increased from 15% to 22% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 19 | Al Altomari | www.agiletherapeutics.com |
Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
Agile Therapeutics, Inc. Fundamentals Summary
AGRX fundamental statistics | |
---|---|
Market cap | US$2.74m |
Earnings (TTM) | -US$14.46m |
Revenue (TTM) | US$19.59m |
0.1x
P/S Ratio-0.2x
P/E RatioIs AGRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AGRX income statement (TTM) | |
---|---|
Revenue | US$19.59m |
Cost of Revenue | US$8.98m |
Gross Profit | US$10.62m |
Other Expenses | US$25.08m |
Earnings | -US$14.46m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.11 |
Gross Margin | 54.18% |
Net Profit Margin | -73.83% |
Debt/Equity Ratio | -10.5% |
How did AGRX perform over the long term?
See historical performance and comparison